This page shows the latest tenofovir alafenamide news and features for those working in and with pharma, biotech and healthcare.
Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) product.
Descovy (emtricitabine/tenofovir alafenamide) claimed its FDA approval for PrEP last week – becoming only the second drug for this use since Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate) got a green
and tenofovir alafenamide) was recently approved by the FDA.
Descovy (emtricitabine and tenofovir alafenamide) has been cleared for adolescents and adults who are at risk of HIV infection because they have sex with an HIV-positive partner. ... In a statement, the FDA said that Descovy’s efficacy in preventing
48-week data from the phase 3 TANGO study indicates that Dovato (dolutegravir/lamivudine) was just as effective as triple therapies that included Gilead’s tenofovir alafenamide fumarate (TAF) at suppressing
bictegravir/emtricitabine/tenofovir alafenamide) product.
More from news
Approximately 4 fully matching, plus 41 partially matching documents found.
With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.